Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Leukotriene D4

Prostanoid receptor ligand
 
BML-LD004-0050 50 µg 262.00 USD
Do you need bulk/larger quantities?
 
Potent agonist for contraction of smooth muscle. Induces microvascular permeability and mucus secretion in airways. Enhances growth of human airway epithelial cells. Reduces myocardial contractility and coronary blood flow. Induces long lasting hypotension. Biosynthesis from LTC4 by γ-glutamyltranspeptidase.

Product Specification

Alternative Name:LTD4
 
Formula:C25H40N2O6S
 
MW:496.7
 
Source:Synthetic.
 
CAS:73836-78-9
 
Concentration:50 µg/ml
 
Formulation:Solution in methanol/ammonium acetate buffer, 70:30, pH 5.6.
 
Purity:≥98% (HPLC)
 
Appearance:Liquid.
 
Shipping:Shipped on Dry Ice
 
Long Term Storage:-80°C
 
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at -80°C. Protect from exposure to air.
 
bml-ld004
Please mouse over
bml-ld004

Product Literature References

Cysteinyl leukotrienes in asthma: old mediators up to new tricks: D. W. P. Hay, et al.; Trends Pharmacol. 16, 304 (1995), Abstract;
Leukotrienes and inflammation: S. D. Brain & T. J. Williams; Pharmacol. Ther. 46, 57 (1990), Abstract;
The signal transduction system of the leukotriene D4 receptor: S. T. Crooke, et al.; Trends Pharmacol. Sci. 10, 103 (1989), Abstract;
Leukotrienes as mediators of ischemia and shock: A. M. Lefer, et al.; Biochem. Pharmacol. 35, 123 (1986), Abstract;
Metabolism of leukotrienes: S. Hammarström, et al.; Mol. Cell Biochem. 69, 7 (1985), Abstract;

Related Products

Cysteinyl leukotriene mixture 

≥90% (HPLC) | Print as PDF
 
BML-SM105-0001 1 Ampoule 166.00 USD
Do you need bulk/larger quantities?
 

Related Literature

Technical Posters
Arachidonic Acid Metabolites
Arachidonic Acid Metabolites
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2018 Enzo Life Sciences, Inc.,